Inside the Top 10 IPOs of 2026

Daily Profit Investing Research
by 

It’s now 9-months into 2026 – and 112 companies have already gone public.

The IPO pipeline is strong – with 194 companies in IPO pipeline. And today, you can invest in my top 5 upcoming IPOs – right before they start trading.

Go here to discover the Pre-IPO secret.

Let’s take a look at the ten best-performing IPOs of 2026.

·       Veradermics (NYSE: MANE) +587%

·       Swarmer (Nasdaq: SWMR) +207%

·       Roze AI (Nasdaq: RZAI) +149%

·       Alamar Biosciences (Nasdaq: ALMR) +102%

·       IMC Rare Earths (NYSE American: IMC) +82%

·       Ethos Technologies (Nasdaq: LIFE) +80%

·       Arxis (Nasdaq: ARXS) +79%

·       Hemab Therapeutics (Nasdaq: COAG) +73%

·       The Elmet Group (Nasdaq: ELMT) +58%

·       Avalyn Pharma (Nasdaq: AVLN) +56%.

What’s the next big winner? Here’s a link to find out my top 5 names.

So, what’s begin these solid IPO winners? Let’s break it down into four key lessons for what’s working in 2026.

Lesson #1: A real raise beats a tiny float. Seven of these companies raised between $126 million and $1.1 billion from largely institutional investors. Arxis, which makes rugged components for aerospace, defense and chip testing, raised $1.13 billion at the top of its range. It has roughly $1.8 billion in trailing revenue and is profitable.

Lesson #2: Day one stock performance tells you very little. Ethos, the online life insurer, fell 11% in its debut. It’s now up 80%. It came public growing fast and profitable, with revenue up 47% and a profit in the nine months before its listing.

Swarmer did the reverse. The drone-swarm software company soared 520% on its first day in March and later hit $83.30. Today it trades at $15.36, more than 80% below that high. It just agreed to buy a Ukrainian ground-robot maker for up to $224 million, though much of that is stock tied to future milestones.

Lesson #3: Clinical data drives biotech. Four of the ten are healthcare names. Veradermics, which is developing an extended-release hair-loss pill, rerated as trial results arrived in April and July. Hemab rests largely on one drug for a rare bleeding disorder. Alamar has about $100 million in revenue but still loses money.

Lesson #4: A hot theme can push a stock well ahead of the business.

Roze AI rode the AI theme to a 149% gain in three sessions. But it’s a direct listing, so existing holders sold shares and the company raised no new money. It fell 24% on Friday alone.

IMC Rare Earths is up 82% on demand for magnet metals produced outside China. It has no revenue yet and a market value near $1 billion after a $20 million raise. If either story stalls, there’s little underneath to hold the price.

So, here’s a short checklist for spotting the next one.

·       Did the company raise enough to fund its plan?

·       Is there revenue growth or a clinical win you can verify?

·       Would the stock still look good if you ignored the first-day jump?

Hopefully this helps provide a little context behind this year’s 10 biggest IPO winners.

Did you know that the “smart money” typically does NOT buy IPO shares? Instead, they invest weeks and months before a major IPO. And that allows them to buy shares at a discount to the actual IPO price.

Here’s how it actually works.

Ian Wyatt
Editor, IPO Watch

To top